Janux Therapeutics Inc (JANX)
47.11
-0.40
(-0.84%)
USD |
NASDAQ |
May 17, 16:00
47.11
0.00 (0.00%)
After-Hours: 20:00
Janux Therapeutics Cash from Operations (Quarterly): -14.84M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -14.84M |
| December 31, 2023 | -9.901M |
| September 30, 2023 | -11.71M |
| June 30, 2023 | -15.05M |
| March 31, 2023 | -13.91M |
| December 31, 2022 | -11.91M |
| September 30, 2022 | -13.41M |
| June 30, 2022 | -6.073M |
| March 31, 2022 | -11.52M |
| Date | Value |
|---|---|
| December 31, 2021 | -10.48M |
| September 30, 2021 | -5.854M |
| June 30, 2021 | -6.204M |
| March 31, 2021 | 5.563M |
| December 31, 2020 | -1.629M |
| September 30, 2020 | -1.083M |
| June 30, 2020 | -0.781M |
| March 31, 2020 | -0.876M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-15.05M
Minimum
Jun 2023
5.563M
Maximum
Mar 2021
-7.628M
Average
-9.901M
Median
Dec 2023
Cash from Operations (Quarterly) Benchmarks
| Viking Therapeutics Inc | -6.134M |
| Equillium Inc | -8.80M |
| Minerva Neurosciences Inc | -6.094M |
| Arvinas Inc | -97.50M |
| Calidi Biotherapeutics Inc | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -113.74M |
| Cash from Financing (Quarterly) | 322.17M |
| Free Cash Flow | -53.26M |
| Free Cash Flow Per Share (Quarterly) | -0.3065 |
| Free Cash Flow to Equity (Quarterly) | -15.03M |
| Free Cash Flow Yield | -2.47% |